Trong mt s nghin cu, glucosamine c bo co l c th gy ra cc vn tiu ha nh kh chu d dy mt s ngi
Rybelsus (oral semaglutide) the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke Novo Nordisk today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use has approved an update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.
Abstract Cancer is a significant public health problem worldwide, and its morbidity and mortality are challenging to improve, which is an important obstacle to prolonging life expectancy
"We believe it will expand access and options for patients," Dr
Mahmood Piraee (PhD, PharmD) Mahmood Piraee (PhD, PharmD) Published Jun 8, 2025 More people than ever are turning to GLP-1 receptor agonists medications originally designed for diabetes, now widely used for weight management
it's well-tolerated and low on the irritation scale